Home > Healthcare & Medical Devices > Pet Cancer Therapeutics Market

Pet Cancer Therapeutics Market Size By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Combination Therapy), By Route of Administration (Oral, Injection), By Species (Dogs, Cats), By Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary and Squamous Cell Cancer), Industry Analysis Report, Regional Outlook, Growth Potential, COVID-19 Impact Analysis, Price Trends, Competitive Market Share & Forecast, 2022 – 2030

  • Report ID: GMI2017
  • Published Date: Aug 2022
  • Report Format: PDF

Industry Overview

Pet Cancer Therapeutics Market size registered a valuation of over USD 270 million in 2021. Driven by growing awareness among pet owners regarding pet diseases, the industry is poised to grow at a CAGR of about 11.2% from 2022 to 2030.
 

Pet Cancer Therapeutics Market

Get more details on this report - Request Free Sample PDF
 

Rising pet adoption will increase the demand for pet cancer therapeutics. The surge in the number of pets affected by cancer will drive the demand for efficient pet cancer therapeutics to manage the condition, fostering the product landscape of the pet cancer therapeutics market.
 

As per the Merck Veterinary Manual, hereditary factors play a role in the occurrence of cancer amongst companion animals. For instance, according to a Frontiers in Oncology Journal article, in the U.S. in 2019, more than 1 million cases of cancer were detected in canines annually. Furthermore, the American Veterinary Medical Association states that more than 50% of dogs develop cancer in their old age.
 

Increasing expenditure on pet care will transform the pet cancer therapeutics industry outlook. Companies are engaging in strategic research and collaborations to enhance their business presence. Additionally, firms also benefit from technological advancements in therapeutics.
 

Side-effects associated with pet cancer therapeutics may restrain industry progression

Various side effects related to pet cancer therapeutics may impact the growth of the pet cancer therapeutics market. Akin to humans, dogs and cats also suffer from vomiting, diarrhea, dehydration, lethargy, low white blood cell count, and bladder irritation as the side effects of chemotherapy. In addition, radiotherapy to treat cancer leads to early and delayed side effects in companion animals, such as redness, irritation, or ulceration on the treated surface area, known as moist desquamation.
 

Consistent success to drive the demand for chemotherapy

Global Pet Cancer therapeutics Market By Therapy

Get more details on this report - Request Free Sample PDF
 

In terms of therapy, the pet cancer therapeutics market is segregated into chemotherapy, immunotherapy, targeted therapy, and combination therapy. The chemotherapy segment is projected to reach over USD 467 million revenue by 2030. Chemotherapy is the most used therapy to treat pet cancer and has been observed to reach remission in over 70% of the cases. Above 95% of dogs suffering from cancer, mainly lymphoma, are estimated to be cured completely through an effective treatment procedure comprising chemotherapy.
 

Oral route of administration to depict massive growth

Based on route of administration, the pet cancer therapeutics industry is categorized into oral and injection. The oral segment is primed to reach a valuation of more than USD 267 million by 2030. Several clinical advantages offered by oral medications, such as the convenience & comfort of home treatment, limited clinic visits, and harmless & non-invasive approach, will fuel segmental growth.
 

Pet cancer therapeutics for dogs to gain traction

In terms of species, the pet cancer therapeutics market is classified into dogs and cats. The dogs segment was valued at nearly USD 261 million in 2021. The prevalence of cancer amongst dogs is much higher than in cats. As per a 2019 report published by Flint Animal Cancer Center, one in every four dogs is most likely to suffer from cancer. High occurrence of cancer among dogs is propelling business statistics.
 

Rising instances of lymphoma to define the industry landscape

Global pet Cancer Therapeutics Market By End - Use

Get more details on this report - Request Free Sample PDF
 

Based on application, the pet cancer therapeutics market is categorized into lymphoma, melanoma, mast cell cancer, mammary & squamous cell cancer, and others. The lymphoma segment accounted for around 25% market share in 2021 and is anticipated to witness notable CAGR through 2030.
 

The growing prevalence of lymphoma, primarily among dogs, is accelerating product uptake. Canine lymphoma is common in middle-aged to old pets. Lymphoma accounts for around 83% of all canine hematological malignancies.
 

High spending on pet therapeutics to help North America emerge as a prominent revenue pocket

Global pet Cancer therapeutics Market By- Region

Get more details on this report - Request Free Sample PDF
 

Regionally, the global pet cancer therapeutics market is divided into North America, Asia Pacific, Europe, and LATAM.
 

The North America industry is anticipated to surpass USD 580 million by 2030. Several factors, including higher spending on pet therapeutics and favorable government policies, are expected to foster market outlook in the region. Supportive initiatives promoting product adoption in the U.S. will prove lucrative for the industry.
 

Another region that may emerge as a key revenue hub is the Asia Pacific. Surging incidences of pet cancer and rising pet care expenditure in APAC are set to drive regional market forecasts.
 

Adoption of advanced technologies to strengthen the pet cancer therapeutics industry outlook

Elanco Animal Health, Zoetis Inc., Merial Inc., AB Science, Anivive Lifesciences, Qbiotics, ELIAS Animal Health, and NovaVive are some major pet cancer therapeutics market players. The industry is relatively consolidated. Firms mainly focus on effective research trials and the development and deployment of efficient treatment methods.
 

For instance, in December 2021, QBiotics initiated the launch of STELFONTA in Australia. The drug has been approved as a therapeutic measure for canine non-metastatic mast cell tumors (MCT) by the Australian Pesticides and Veterinary Medicines Authority (APVMA).
 

Impact of COVID-19 on the pet cancer therapeutics industry trends

COVID-19 slightly slowed the growth of the pet cancer therapeutics market chiefly during the initial phase of 2020 as pet owners readily adopted medications for ensuring the well-being of their pets. However, following the peak of the pandemic in 2020, the demand for pet therapeutics did not decline as pet owners actively tried to ensure the well-being of their pets. Various animal welfare organizations collaborated in different parts of the world to offer seamless services to pet owners.
 

The Pet Cancer Therapeutics market report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2030 for the following segments:

By Therapy

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Combination Therapy

By Route of Administration,

  • Oral
  • Injection

By Species

  • Dogs
  • Cats

By Application

  • Lymphoma
  • Mast Cell Cancer
  • Melanoma
  • Mammary and Squamous Cell Cancer
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia 
  • Latin America
    • Brazil
    • Mexico

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

The pet cancer therapeutics market was valued at over USD 270 million in 2021 and is set to expand at a CAGR of over 11.2% over the forecast period.

The pet cancer therapeutics market share from the lymphoma application segment is expected to showcase notable growth by 2030 owing to the mounting prevalence of lymphoma, primarily among dogs.

The chemotherapy segment is slated to record substantial expansion to attain a valuation of above USD 467 million by the end of 2030 since it is the most common therapy used to treat pet cancer.

The North America market for pet cancer therapeutics is expected to account for more than USD 580 million in revenue by 2030 owing to rising incidences of pet cancer and high expenditure on pet therapeutics.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies
Immediate Delivery Available

Premium Report Details

  • Base Year: 2021
  • Companies covered: 8
  • Tables & Figures: 201
  • Countries covered: 13
  • Pages: 145

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount